Skip to main content
Clinical Trials/NCT03248388
NCT03248388CompletedNot Applicable

Utility of Visual Pattern Recognition Technology in Retinal Prosthesis Patients: the ARGUSII/ORCAM Device Study

Mayo Clinic1 site in 1 country4 target enrollmentStarted: August 31, 2017Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
4
Locations
1
Primary Endpoint
Number of Subjects Who Are Able to Use the ORCAM device With the Argus II Device at the End of the Study

Study Overview

Brief Summary

This study is being done to determine if wearable text-to-speech (TTS) and visual pattern recognition (VPR) technology can be used to extend the capabilities of the Argus II to allow patients to read and recognize faces and objects.

The Argus II retinal prosthesis can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition. The FDA has approved the Argus II as a humanitarian device.

Present-day wearable text-to-speech converters are also capable of object and face recognition. Such systems have been developed to assist with these tasks in patients with severe low-vision. ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.

Detailed Description

The Orcam device will be mounted onto the Argus II eyeglasses. The subject will be asked to use the Orcam device with and without the Argus II. After a half-day interactive training session with the Orcam device, the investigators will interview the subject with a questionnaire. The investigators will then contact the subject every two weeks via a telephone call for two months (4 phone interviews). The investigators will then ask the subject to return to Mayo Clinic to demonstrate their ability to use the Argus II and Orcam together and separately. These sessions will be videotaped.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Device Feasibility
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Diagnosis of advanced retinitis pigmentosa
  • •Subjects must have an Argus II device implanted to be eligible for this study
  • •Subjects must be familiar with using their Argus II device

Exclusion Criteria

  • •No Argus II implant

Arms & Interventions

Adults with Retinitis Pigmentosa using ARGUS II

Experimental

Subjects will use the ORCAM system mounted onto the Argus II eyeglasses.

Intervention: Argus II Eyeglasses (Device)

Adults with Retinitis Pigmentosa using ARGUS II

Experimental

Subjects will use the ORCAM system mounted onto the Argus II eyeglasses.

Intervention: ORCAM (Device)

Outcomes

Primary Outcomes

Number of Subjects Who Are Able to Use the ORCAM device With the Argus II Device at the End of the Study

Time Frame: End of study, approximately 4 months

Subjects will be familiar with using their retinal prosthesis, the Argus II Device. At baseline, the ORCAM device will be mounted on the Argus II eyeglasses.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Raymond Iezzi

Associate Professor of Ophthalmology

Mayo Clinic

Study Sites (1)

Loading locations...

Similar Trials